Scientific Areas of Interest
What's under the microscope, and beyond.
The discovery of new medicines is about being relentless. You will gain access to Lilly development team with decades of experience dedicated to exploring every avenue necessary.
We never stop searching for:
- Medicines that are novel, tailored and differentiated from the current standard of care.
- New ways to address unmet medical needs.
- Treatments, therapies, technologies and devices that generate better outcomes for payers, providers, prescribers and patients.
And it's all done with a true sense of urgency, ensuring our medicines reach patients as soon as possible.
Neither the content nor any other service presented here is intended to be relied on for medical diagnosis or treatment.
At Lilly Oncology, we seek enabling therapeutic development platforms, breakthrough monotherapy programs, and opportunities for rational combinations with our existing pipeline.
Immuno-oncology approaches: Therapies focused on neoantigens, T-cell redirection, novel checkpoint agents and disruptive immunotherapy targets/platforms
Tumor metabolism pathway modulators: Agents targeting the tumor microenvironment and interplay between the mircroenvironment, immune system and tumor energetics
Novel approaches targeting tumor dependencies in molecularly enriched populations
Modulating epigenetic pathways
Click here Oncology for PDF version.
- Novel therapeutic approaches for disease modification in neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease
- Novel treatments that address the symptoms of neurodegenerative disease including psychosis, cognitive impairment, agitation, mood and sleep
- Blood-based biomarkers for early detection of amyloid-positive dementia
- Wearable technologies and smartphone applications for early detection of Alzheimer's disease initiation and progression
Pain and Migraine
- Novel approaches to treat chronic neuropathic, inflammatory and visceral pain
- Migraine prophylaxis
Click Neuroscience for PDF version.
Insulins and Glucagon:
- Next-generation insulins (basal, ultra-rapid, high-concentration, thermostable)
- Glucose-responsive/sensing insulin
- Soluble glucagon
- Novel GLP-1 and dual-acting GLP-1 mimetics and novel combinations with potential for CV benefits
- Novel approaches relevant to the development of an artificial pancreas
- Oral peptide/protein delivery platforms and therapeutics
- Breakthrough diabetes device technology
Diabetic Complications and Novel Disease Modifiers:
- Diabetes regression and durability of response
- Pathways and mechanisms that impact breakthrough weight loss (e.g., >10%) and insulin sensitization
- Diabetic kidney disease Pathways and mechanisms related to inflammation, endothelial dysfunction (hemodynamic), remodeling and alteration of tissue metabolism
NAFLD/NASH Intersecting pathways of lipid metabolism, insulin sensitization and weight loss
- CV: Diabetic dyslipidemia with MACE benefits Agents that have beneficial effects on multiple lipid/vascular risk factors such as triglyceride, LDL-C and Lp(a)
- CV: Heart failure HFrEF and HFpEF; novel mechanisms that can be used in conjunction with the existing standard of care. Areas of focus include targets that impinge on cardiac substrate utilization and metabolism, remodeling and vascular health
- RNAi, translational modulators, cell-based therapy (e.g., for T1DM, heart failure)and microbiome modulators
- Type 1 Diabetes
- Endocrine disorders (e.g., growth disorders and major unmet medical needs)
- Neuropathic pain (intersects with our Pain TA)
- Novel mechanisms: Especially in the private sector, new/emerging companies and/or mechanisms that are not addressed above
- Differentiation is key. Highest priority is given to validated 'Glucose-Plus' agents (i.e., drugs that reduce HbA1c and elicit >10% weight loss and/or improvements in other CV risk factors); essentially therapeutics that can mimic bariatric surgery-like effects
Out of Scope:
- Insulin secretagogues with no added metabolic benefits
- Wound healing
- Acute myocardial infarction/ischemia-reperfusion therapies
- Acute/ischemic stroke
- Peripheral arterial disease
Click Diabetes Related Complications for PDF version.
The immunology platform’s mission is to address unmet medical needs with best-in-disease or best-in-class medicines and to deliver unparalleled customer experiences—with a strong focus on small molecule and biologics in the following indications:
Indications in Scope:
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Crohn’s disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Lupus nephritis
- Atopic dermatitis
Technologies in Scope:
- Interested in small molecule NMEs with biologic efficacy, and no increased safety risk
- Antibodies that have a durable MOA with a greatly improved clinical efficacy over standard of care
- Nanoparticles for use in tolerance
Out of Scope:
- Intergin targets
Click Immunology for the PDF version.
The Emerging Technology and Innovation team complements therapeutic area-specific external research efforts by providing distinct geographic coverage plus access to novel pathways and new therapeutic modalities. We specialize in connecting partners to Lilly expertise and deploying flexible funding models. The team is comprised of experienced drug discovery and development scientists based in Cambridge, Mass.(external research hub established 2016), Indianapolis and Europe, with additional members in Japan.
New opportunities of interest include pan-therapeutic and adjacent disease areas (as well as added support for Lilly’s core therapeutic areas). We are committed to collaboration with premier universities, investigators and companies around the world to advance innovation, enhance Lilly’s pipeline and improve patient outcomes.
Novel Biologic Pathways: Emphasis on those with multi-therapeutic area potential.
- Examples include: micro-RNA; exosome biology; epigenetics
Adjacent Disease Areas:
- Examples include: fibrosis, kidney disease, vascular disease, other disorders of immune function, broader neurologic conditions
- New therapeutic modalities (including but not limited to, oligonucleotide-based approaches, gene editing, gene therapy, microbiome, cell-based approaches)
- Novel approaches to “drug” difficult targets (e.g., cell-penetrant peptide platforms)
Alternative Funding and Partnering Models: This team has expertise in—and access to—flexible funding models for advancing exciting science.
- Strategic limited partnerships in world-class venture funds. These funds work with scientific and business leaders to advance breakthrough innovation. A key strategy involves early development funding and co-funding opportunities (emphasis on leveraging Lilly’s Chorus* organization)
- Direct equity investments in selected biotechnology companies
- “Build-to-buy” investments
- Other “shared-risk” drug discovery and early development relationships
- Chorus is a fully integrated early stage drug development team whose scope includes IND-enabling preclinical studies through Phase 2 development. Chorus specializes in delivery of rapid, efficient and cost–effective clinical proof-of-concept results. The team has extensive experience in developing externally derived molecules in partnership with selected VC firms (including HealthCare Ventures, TVM Capital, Atlas Ventures).
Click Emerging technology and innovation for PDF version.
Biotherapeutic Discovery and Validation:
- Antibody discovery: in vitro and in vivo
- Antibody screening platforms; e.g., microfluidics
- Novel immunization platforms
- Ion channels
- Bi-specific/multi-functional platforms
- Alternative antibody scaffolds
- Protein engineering
- Translational cell-based platforms – 3D culture; e.g., 3D printing – ‘Organ on a chip’ nanotechnology
- iPS cell differentiation
- Vascular endothelial cell biology
- Protein expression/production technologies – Non-mammalian/microbial expression and production systems – Cell line generation – Cell culture – Antibody/Fab production systems
- Purification processes
- Glycosylation, including non-mammalian
- Peptide chemistry – Semi-synthetic or recombinant – Non-natural amino acid incorporation
- Protein: protein interactions – Macrocyclics
- Peptide/Protein drug conjugates
- Novel linker/conjugation chemistries
- Time extension of antibodies, peptides and proteins
- Size: alternatives to PEG-ylation
- Controlled release
- Site-specific chemical modification
- Biophysical analysis
- Mass spectrometry data analysis tools
- Charaterization of particle mass, composition, morphology; i.e., >1 um
- Protein structure at higher resolution than CD, FTIR, etc.
- Automated formats for existing biophysical techniques; e.g., static light scattering
- Protein colloidal stability/protein-protein interactions at >100+mg/mL
- Permeation enhancers, receptor-mediated transcytosis, nanotechnologies
- Blood-brain barrier
- Capillary endothelial barrier
- Pericellular junctions (subQ delivery)
- Intracellular targeting
- Formulation design
- Excipients, co-formulations, nanotechnologies
- In vivo targeted delivery of nucleic acid-based molecules
Click Biotechnology Discovery Research for PDF version.
Connected Product Systems:
- Connected injection and diagnostic devices
- Next-generation miniaturized electronics (sensing, power, communications, processing)
- Robust analytics platforms that provide actionable insights
- Novel, low-cost, real-time, non-or minimally-invasive biosensing or digital biomarker platforms
- Personalized, prescriptive algorithms/machine learning for disease management
- Technology-enabled services to support customers achieving better outcomes
- Data integration platform technologies that securely integrate disparate health and contextual data sources to enable a connected ecosystem that achieves better outcomes at lower cost and higher quality
- Medial algorithms for use in mobile medical applications
- Formulation technology to reduce viscosity and/or enhance stability of biologics
- Needle-free delivery technologies
- Time-action modulation (small and large molecules)
- Preservation technology to enable multi-use biological preps
- Device technology, including body-worn devices, to rapidly deliver high-volume (>2ml) and/or high-viscosity (>10 cpd) biologic solutions
- Multi-pharmacology delivery systems, including fixed-dose combinations and bi-specific or combined dose antibodies
- Technologies to increase concentration of proteins
- Longer stabilization or eliminated/reduced preservative insulin technologies
Oral Biologic Deliver:
- Formulation technology
- Molecular engineering
- High oral bioavailability system for large(r) molecules
Click Devices delivery and connected care for PDF version.
In-Licensing and Co-Development
- Thoracic cancer and breast cancer
- Gastrointestinal: Gastric, colorectal, hepatocellular carcinoma, pancreatic cancer
- Rheumatoid arthritis
- Psoriasis, psoriatic arthritis, anklyosing spondylitis
- Systemic lupus erythematosus, lupus nephritis
- Crohn's disease and ulcerative colitis
- Neurodegenerative disorders: Approaches that affect disease progression or modification and/or address major symptoms of the disease
- Pain and Migraine
- Glucose and metabolic control: ultra rapid-acting insulins, novel oral anti-diabetic agents, novel insulin sensitizers
- Endocrine disorders (e.g., growth disorders)
- Connected product systems: Connected injection devices, analytics platforms that provide actionable insights
Click Lilly International for PDF version.
- Full-service, autonomous R&D unit within Lilly
- Specializes in drug development from candidate selection to clinical proof-of-concept (PoC)
- Focuses only on those experiments that can provide quick go/no go decisions and create strong PoC data packages
- Pulls risk forward and increases marketability of the development program by implementing development work that drives the largest change in technical probability of success and greatest value in the shortest time
- Pioneered and validated the built-to-buy early development model for Lilly
The Chorus lean-and-efficient model improves productivity in both time and cost compared to average pharmaceutical R&D metrics. Since its creation in 2002, Chorus has completed more than 50 internal Lilly and external-sponsored programs in various clinical indications in 19 countries.
Click Chorus for PDF version.
At Elanco, we provide those who raise and care for animals with solutions that empower them to advance a vision of food and companionship enriching life.
We understand the powerful role healthy animals play in making lives better. As pets increasingly become important parts of our families, so too does the need to help them live longer, healthier, higher-quality lives. As the global population grows, so too will the need to meet the demand for safe, affordable food for all.
Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. We strive to develop and deliver products safe for consumers, animals and the environment through innovation and a shared vision to enrich the lives of people worldwide.
External Innovation Elanco’s partnership engine providing rapid evaluation of external opportunities for both Companion and Food Animals.
Partnering with Elanco
- Global presence in food animal and companion animal markets
- Significant sales and marketing capabilities in health and nutrition
- Extensive R&D capabilities with an innovative pipeline and approach
- Create alternative revenue streams and discover unrealized commercial value
Animal Health Licensing
- Potentially faster route to market/income to support additional development efforts
- Rapid proof-of-concept in the target species
- Opportunities that fail in human health may become successful animal health products through re-purposing and may provide extended patent life
Food and Companionship Enriching Life Focused R&D Efforts Elanco Table Picture
Click Animal health for PDF version.
Discovery Chemistry Research & Technologies (DCRT) invents and discovers new molecules that can become medicines. These molecules must have the right characteristics to test innovative therapeutic hypotheses and be differentiated from those of our competitors. To achieve this, DCRT works with all therapeutic areas to choose the right biological targets whose manipulation may lead to positive patient outcomes. DCRT brings together many different scientific disciplines to design, prepare, and select the best molecular scaffolds for optimization, with the ultimate goal of delivering a single molecule that has the best combination of attributes to be tested in the clinic.
Molecule Design & Identification:
- In silico & related technologies
- Computational chemistry
- Cheminformatics & bioinformatics
- Analytical methodologies & instrumentation
- Complementary chemical diversity
- DNA-encoded libraries
- Oral strategies for high MW molecules
- Protein: Protein interaction inhibitors
Molecule Synthesis & Optimization:
- Automation hardware & software
- Human disease-relevant in vitro cell-based assays
- Novel biological targets & assay approaches
- Structural biology and biophysical methods to study Mode of Action
- Biophysical technologies
Click Discovery chemistry research for PDF version.
The Lilly Biotechnology Center in San Diego (LBC-SD) is seeking academic and biotechnology partners interested in leveraging our protein discovery and engineering capabilities to advance research on novel therapeutic targets and pathways into clinical translation. With our ability to create a large molecule diversity via robust antibody and peptide discovery technologies, a collaboration with LBC-SD allows the rigorous interrogation and validation of novel targets. Our engineering capabilities allow pursuit of flexible strategies of multi-parameter optimization to solve key issues with pharmacology, drugability and down-stream developability spanning traditional scaffolds to next-generation multifunctionals. These varied scaffolds (including antibodies, hormones, cytokines and enzymes) have successfully been applied to a broad range of clinical targets.
TCMR collaborates with external scientific organizations (biotechs, start-ups, universities, government agencies) to de-risk early human health drug discovery packages by applying proof-of-concept studies from the naturally occurring diseases in companion animals that parallel human diseases.
- An extensive full-service R&D unit within Elanco, a division of Eli Lilly and Company
- In-house veterinary scientists, clinical specialists and operational experts
- Specialize in pre-clinical, drug development with a focus on informing go/no go decisions and creating strong proof-of-concept data packages
- Specialize in the design and implementation of companion animal studies in diseases with parallel human diseases, such as, but not limited to:
- Heart failure
- High-quality safety and efficacy data from companion animals with naturally occurring diseases that parallel human diseases can increase the marketability of proof-of-concept data packages, particularly for target diseases with high failure rates in Phase II and III clinical trials
Click Translational and Comparative Medical Research for PDF version.